EC
SANA icon

EntryPoint Capital’s Sana Biotechnology SANA Stock Holding History

EntryPoint Capital’s Portfolio SANA Stock Details SANA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-27,345
Closed -$114K – 936
2024
Q3 		$114K Buy
27,345
+5,013
+22% +$26.3K 0.06% 547
2024
Q2 		$122K Buy
22,332
+20,575
+1,171% +$164K 0.06% 705
2024
Q1 		$17.6K Buy
+1,757
New +$13.2K 0.02% 1131

Other funds holding SANA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

EntryPoint Capital's SANA Position: Q4 2024 in Review

EntryPoint Capital sold out of Sana Biotechnology (SANA) in Q4 2024, closing a stake of 27,345 shares — an estimated $114K sold.

EntryPoint Capital first reported a position in SANA in Q1 2024 and held it in 3 quarters. The position peaked at $122K in Q2 2024. 164 funds tracked by Wall St. Rank hold SANA as of Q4 2024.

  • EntryPoint Capital reported no remaining Sana Biotechnology position as of Q4 2024 after selling out during the quarter.
  • EntryPoint Capital sold 27,345 Sana Biotechnology shares in Q4 2024, an estimated $114K.
  • EntryPoint Capital first reported a position in Sana Biotechnology in Q1 2024 and held it in 3 quarters.
  • EntryPoint Capital's Sana Biotechnology position peaked at $122K in Q2 2024.
  • 164 funds tracked by Wall St. Rank held Sana Biotechnology as of Q4 2024.

Based on EntryPoint Capital's 13F filing for Q4 2024, filed 11 Feb 2025.